In O
addition O
, O
the O
Ah B
receptor I
complex I
recognized O
a O
DNA B
binding I
site I
for O
B B
cell I
lineage I
- I
specific I
activator I
protein I
( O
BSAP B
) O
in O
the O
promoter B
region I
of O
the O
human O
CD19 B
gene I
which O
is O
similar O
to O
the O
consensus B
Ah I
receptor I
DNA I
binding I
site I
. O

These O
results O
imply O
that O
at O
least O
three O
signals O
are O
required O
to O
activate O
the O
GM B
- I
CSF I
proximal I
promoter I
, O
and O
that O
the O
signals O
impinge O
on O
distinct O
transcription B
factors I
that O
bind O
to O
the O
hCLEO B
and I
NF I
- I
kappa I
B I
regions I
of O
the O
promoter B
. O

The O
promoters B
were O
used O
without O
enhancers B
, O
or O
with O
enhancers B
derived O
from O
the O
beta B
- I
globin I
locus I
control I
region I
and O
the O
alpha B
- I
globin I
HS I
- I
40 I
enhancer I
. O

To O
identify O
other O
factors O
which O
interact O
with O
the O
LMP B
- I
1 I
EBNA I
- I
2 I
response I
element I
( O
E2RE B
) O
, O
a O
- B
236 I
/ I
- I
145 I
minimal I
E2RE I
was O
used O
as O
a O
probe O
in O
an O
electrophoretic O
mobility O
shift O
assay O
. O

Abnormal O
fast O
feedback O
and O
negative O
feedback O
of O
the O
hypothalamic O
- O
pituitary O
- O
adrenal O
axis O
implicates O
a O
dampened O
limbic B
- I
hippocampal I
glucocorticoid I
type I
II I
receptor I
( O
GCII B
) O
. O

Thapsigargin O
( O
TG O
) O
, O
an O
inhibitor O
of O
Ca B
( I
2 I
+ I
) I
- I
ATPase I
, O
depletes O
intracellular O
Ca2 O
+ O
stores O
and O
induces O
a O
sustained O
Ca2 O
+ O
influx O
without O
altering O
phosphatidyl O
inositol O
levels O
. O

The O
constitutive O
NF B
- I
kappa I
B I
appears O
to O
be O
functionally O
active O
, O
since O
a O
low O
level O
of O
tumour B
necrosis I
factor I
( I
TNF I
) I
transcript I
is O
detectable O
in O
monocytes O
, O
and O
this O
level O
can O
be O
increased O
by O
blocking O
transcript O
degradation O
using O
cycloheximide O
. O

The O
B B
cell I
- I
associated I
surface I
molecule I
CD40 I
functions O
to O
regulate O
B O
cell O
responses O
. O

The O
sequence O
between O
position O
- B
42 I
and I
- I
76 I
base I
pairs I
( O
bp O
) O
was O
required O
for O
efficient O
transcription O
in O
cells O
that O
express O
alpha B
4 I
, O
but O
it O
showed O
no O
activity O
in O
HeLa O
cells O
, O
which O
do O
not O
express O
alpha B
4 I
. O

The O
transmission O
of O
signals O
from O
the O
membrane O
to O
the O
nucleus O
is O
mediated O
principally O
through O
the O
action O
of O
protein B
tyrosine I
and I
serine I
/ I
threonine I
kinases I
. O

Our O
studies O
reveal O
that O
inactivation O
of O
the O
v B
- I
abl I
protein I
tyrosine I
kinase I
triggers O
high O
- O
frequency O
rearrangement O
of O
kappa B
and I
lambda I
light I
- I
chain I
genes I
. O

Corticosteroid B
Type I
I I
and I
Type I
II I
receptors I
are O
inversely O
correlated O
with O
age O
. O

Analysis O
of O
the O
chromatin O
organization O
of O
the O
integrated O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
genome I
has O
previously O
revealed O
a O
major B
constitutive I
DNase I
I I
- I
hypersensitive I
site I
associated O
with O
the O
pol B
gene I
( O
E O
. O
Verdin O
, O
J O
. O
Virol O
. O
65 O
: O
6790 O
- O
6799 O
, O
1991 O
) O
. O

We O
have O
previously O
shown O
that O
a O
human O
B O
lymphoma O
cell O
line O
, O
B104 O
, O
expressed O
surface B
IgM I
( O
sIgM B
) O
and O
surface B
IgD I
( O
sIgD B
) O
, O
and O
that O
crosslinking O
of O
sIgM B
and O
sIgD B
by O
anti B
- I
IgM I
antibody I
( I
Ab I
) I
and O
anti B
- I
IgD I
Ab I
, O
respectively O
, O
induced O
Ca2 O
+ O
influx O
to O
almost O
the O
same O
degree O
, O
whereas O
only O
sIgM B
- O
crosslinking O
caused O
B104 O
cell O
death O
. O

Therefore O
, O
to O
evaluate O
the O
mechanism O
of O
TPA O
responsiveness O
of O
the O
SNE B
motifs I
and O
of O
a O
related O
16 O
- O
bp O
SEE B
( O
SRF B
/ I
ETS I
element I
) O
motif O
found O
in O
the O
HCMV B
and I
chimpanzee I
CMV I
MIE I
enhancers I
, O
we O
have O
examined O
the O
functional O
responses O
and O
protein O
binding O
properties O
of O
multimerized B
wild I
- I
type I
and I
mutant I
elements I
added O
upstream O
to O
the O
SCMV B
MIE I
or O
simian B
virus I
40 I
minimal I
promoter I
regions I
in O
the O
U O
- O
937 O
, O
K O
- O
562 O
, O
HL O
- O
60 O
, O
THP O
- O
1 O
, O
and O
Jurkat O
cell O
lines O
. O

S107 O
plasmacytoma O
cells O
, O
which O
express O
CD40 B
but O
are O
defective O
for O
the O
nuclear O
appearance O
of O
p50 B
/ I
p65 I
- I
NF I
- I
kappaB I
, O
do O
not O
express O
RelB B
after O
CD40 B
stimulation O
. O

We O
identified O
an O
86 O
- O
nucleotide O
fragment O
that O
is O
90 O
% O
identical O
to O
the O
recently O
characterized O
murine B
IL I
- I
2 I
- I
responsive I
element I
( O
mIL B
- I
2rE I
) O
. O

The O
IRF B
- I
2 I
promoter B
region I
contains O
a O
CpG O
island O
, O
with O
several O
GC B
boxes I
, O
a O
putative O
NF B
- I
kappa I
B I
- I
binding I
site I
, O
and O
a O
CAAT B
box I
, O
but O
no O
TATA B
box I
. O

Characterization O
of O
the O
murine B
cyclin I
- I
dependent I
kinase I
inhibitor I
gene I
p27Kip1 B
. O

Silencing O
of O
human O
fetal O
globin B
expression O
is O
impaired O
in O
the O
absence O
of O
the O
adult B
beta I
- I
globin I
gene I
activator I
protein I
EKLF B
. O

In O
conclusion O
, O
E B
( I
gre I
) I
motifs O
and O
interacting O
basic B
helix I
- I
loop I
- I
helix I
proteins I
are O
important O
determinants O
for O
MLV O
transcriptional O
activity O
in O
lymphocytic O
cell O
lines O
. O

Tyloxapol O
inhibits O
activation O
of O
the O
transcription B
factor I
nuclear I
factor I
- I
kappa I
B I
( O
NK B
- I
kappa I
B I
) O
, O
reduces O
resting O
secretion O
of O
the O
cytokine B
interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
in O
cultured O
human O
monocytes O
, O
and O
inhibits O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
release O
of O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
the O

Tyloxapol O
inhibits O
activation O
of O
the O
transcription B
factor I
nuclear I
factor I
- I
kappa I
B I
( O
NK B
- I
kappa I
B I
) O
, O
reduces O
resting O
secretion O
of O
the O
cytokine B
interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
in O
cultured O
human O
monocytes O
, O
and O
inhibits O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
release O
of O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
the O

In O
this O
study O
, O
we O
examined O
the O
molecular O
mechanism O
by O
which O
agents O
that O
elevate O
intracellular O
cAMP O
inhibit O
the O
expression O
of O
the O
tumor B
necrosis I
factor I
alpha I
( O
TNFalpha B
) O
, O
tissue B
factor I
, O
endothelial B
leukocyte I
adhesion I
molecule I
- I
1 I
, O
and O
vascular B
cell I
adhesion I
molecule I
- I
1 I
genes I
. O

The O
previously O
defined O
minimal B
enhancer I
containing O
the O
muA B
, I
muE3 I
, I
and I
muB I
sites I
is O
transactivated O
by O
a O
combination O
of O
the O
ETS B
- I
domain I
proteins I
PU B
. I
1 I
and O
Ets B
- I
1 I
in O
nonlymphoid O
cells O
. O

To O
determine O
the O
contribution O
of O
the O
cytoplasmic B
domain I
of O
the O
IL B
- I
7 I
receptor I
alpha I
chain I
( O
IL B
- I
7R I
alpha I
) O
to O
activation O
of O
STAT B
proteins I
, O
transfectants O
of O
the O
murine O
pro O
- O
B O
cell O
line O
BAF3 O
were O
made O
that O
express O
chimeric B
receptors I
consisting O
of O
the O
extracellular B
domain I
of O
human B
granulocyte I
colony I
- I
stimulating I
factor I
receptor I
( O
G B
- I
CSF I
- I
R I
) O
and O
the O
transmembrane B
and I
intracellular I
domains I
of O
human B
IL I
- I
7R I
alpha I
. O

However O
, O
transcriptional O
activation O
was O
only O
observed O
from O
a O
VitD3 B
response I
element I
- I
driven I
reporter I
construct I
. O

The O
IL B
- I
10R I
, O
together O
with O
reporter O
gene O
constructs O
containing O
different O
IL B
- I
6 I
- I
responsive I
gene I
elements I
, O
reconstituted O
in O
hepatoma O
cells O
an O
induction O
of O
transcription O
by O
IL B
- I
10 I
that O
was O
comparable O
to O
that O
by O
IL B
- I
6 I
. O

Triplex O
formation O
by O
GM3 O
blocked O
recombinant B
and I
nuclear I
NF I
- I
kappaB I
proteins I
binding O
to O
the O
GM B
- I
CSF I
element I
. O

Using O
these O
T O
cells O
as O
a O
model O
of O
IL B
- I
12 I
signal O
transduction O
, O
we O
confirmed O
that O
these O
events O
involve O
members O
of O
the O
Janus B
kinase I
family I
of O
nonreceptor B
tyrosine I
kinases I
JAK2 B
, O
TYK2 B
, O
and O
signal B
transducer I
and I
activator I
of I
transcription I
4 I
. O

r B
- I
hTBP I
- I
1 I
and O
rhu B
TNFR I
: I
Fc I
also O
decreased O
p24 B
antigen I
synthesized O
by O
U1 O
cells O
in O
response O
to O
other O
stimuli O
, O
including O
phytohemagglutinin B
( I
PHA I
) I
- I
induced I
supernatant I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
, O
interleukin B
- I
6 I
, O
and O
TNF B
. O

r B
- I
hTBP I
- I
1 I
and O
rhu B
TNFR I
: I
Fc I
also O
decreased O
p24 B
antigen I
synthesized O
by O
U1 O
cells O
in O
response O
to O
other O
stimuli O
, O
including O
phytohemagglutinin B
( I
PHA I
) I
- I
induced I
supernatant I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
, O
interleukin B
- I
6 I
, O
and O
TNF B
. O

A O
mutant O
Tax B
protein I
deficient O
in O
transactivation O
of O
genes O
by O
the O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
pathway O
was O
unable O
to O
induce O
transcriptional O
activity O
of O
IL B
- I
1alpha I
promoter I
- I
CAT I
constructs I
, O
but O
was O
rescued O
by O
exogenous O
provision O
of O
p65 B
/ I
p50 I
NF B
- I
kappaB I
. O

A O
mutant O
Tax B
protein I
deficient O
in O
transactivation O
of O
genes O
by O
the O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
pathway O
was O
unable O
to O
induce O
transcriptional O
activity O
of O
IL B
- I
1alpha I
promoter I
- I
CAT I
constructs I
, O
but O
was O
rescued O
by O
exogenous O
provision O
of O
p65 B
/ I
p50 I
NF B
- I
kappaB I
. O

Mutation O
of O
the O
consensus B
AP I
- I
1 I
/ I
CRE I
site I
within O
ZII B
abolished O
the O
inducibility O
of O
Zp B
by O
HHV O
- O
6 O
, O
whereas O
positioning O
of O
the O
ZII B
domain I
upstream O
of O
the O
beta B
- I
globin I
minimal I
promoter I
conferred O
responsiveness O
following O
HHV O
- O
6 O
infection O
. O

Antibodies O
against O
CRE B
- I
binding I
( I
CREB I
) I
protein I
but O
not O
against O
c B
- I
Fos I
or O
c B
- I
Jun I
were O
able O
to O
supershift O
the O
DNA B
- I
protein I
complex I
, O
identifying O
the O
nature O
of O
the O
transcription B
factor I
which O
binds O
to O
ZII B
as O
a O
member O
of O
the O
CREB B
family I
of I
proteins I
. O

After O
several O
round O
of O
subcloning O
followed O
by O
transfection O
, O
oriP B
was O
mapped O
to O
a O
1 B
. I
955 I
- I
kb I
viral I
segment I
. O

The O
importance O
of O
NF B
- I
kappaB I
sites I
was O
confirmed O
by O
using O
vectors O
containing O
wild B
- I
type I
or I
mutant I
kappaB I
sites I
in O
a O
heterologous B
promoter I
. O

PU B
. I
1 I
is O
a O
hematopoietic B
- I
specific I
Ets I
family I
transcription I
factor I
that O
is O
required O
for O
development O
of O
some O
lymphoid O
and O
myeloid O
lineages O
. O

Furthermore O
, O
SLP B
- I
76 I
and O
Vav B
have O
a O
synergistic O
effect O
on O
interleukin B
( I
IL I
) I
- I
2 I
promoter I
activity O
in O
T O
cells O
. O

RCC O
- O
S O
did O
not O
alter O
the O
cytoplasmic O
levels O
of O
RelA B
and O
NF B
- I
kappaB1 I
but O
did O
suppress O
their O
nuclear O
localization O
and O
inhibited O
the O
activation O
of O
RelA B
/ I
NF I
- I
kappaB1 I
binding I
complexes I
. O

STAT1 B
activity O
was O
evident O
on O
the O
STAT B
binding I
sequences I
( O
SBE B
) O
present O
in O
the O
promoters B
of O
genes O
which O
are O
up O
- O
regulated O
during O
monocyte O
to O
macrophage O
maturation O
such O
as O
FcgammaRI B
and O
ICAM B
- I
1 I
, O
and O
in O
the O
promoter O
of O
the O
transcription B
factor I
IFN I
regulatory I
factor I
- I
1 I
. O

We O
have O
localized O
a O
317 O
base O
pair O
cis B
- I
acting I
regulatory I
element I
, O
HS B
I I
, O
associated O
with O
a O
hematopoietic B
- I
specific I
DNase I
I I
hypersensitive I
site I
, O
which O
lies O
approx O
. O

A O
PMA B
responsive I
element I
was O
localized O
to O
a O
region O
between O
- B
319 I
and I
- I
219 I
bp I
upstream I
of O
the O
initiation O
codon O
and O
co O
- O
transfections O
with O
transcription B
factor I
expression I
plasmids I
for O
AP B
- I
2 I
and O
Sp1 B
resulted O
in O
augmented O
ASM O
promoter O
activity O
, O
which O
was O
abolished O
when O
the O
binding B
sites I
for O
these O
two O
factors O
were O
deleted O
. O

Characterization O
of O
expression O
of O
the O
gene O
for O
human B
pterin I
carbinolamine I
dehydratase I
/ I
dimerization I
cofactor I
of O
HNF1 B
. O

In O
contrast O
, O
HePTP B
had O
no O
effects O
on O
N B
- I
terminal I
c I
- I
Jun I
kinase I
or O
on O
events O
upstream O
of O
the O
MAP O
kinases O
. O

RA O
previously O
was O
found O
to O
inhibit O
granulocyte B
colony I
- I
stimulating I
factor I
- O
- O
and O
not O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
- O
- O
stimulated O
proliferation O
of O
CD34 O
+ O
cells O
. O

A O
cdk2 O
inhibitor O
, O
Olomoucine O
, O
as O
well O
as O
a O
dominant B
- I
negative I
cdk2 I
construct I
prevented O
HLA B
class I
I I
- O
mediated O
inactivation O
of O
Rb B
; O
in O
contrast O
, O
dominant B
- I
negative I
cdk4 I
and I
cdk6 I
constructs I
had O
no O
effect O
. O

The O
I B
gamma I
3 I
ECS B
lies O
upstream O
of O
the O
major B
I I
gamma I
3 I
transcription I
initiation I
site I
and O
displays O
more O
than O
90 O
% O
identity O
with O
the O
corresponding O
human B
I I
gamma I
1 I
, O
I B
gamma I
2 I
, O
and O
I B
gamma I
4 I
regions O
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
p50 B
/ I
p65 I
/ I
c I
- I
Rel I
and O
STAT B
- I
6 I
are O
effectively O
induced O
by O
CD40L B
and O
IL B
- I
4 I
, O
respectively O
, O
and O
bind O
to O
specific O
DNA B
motifs I
within O
the O
ECS B
. O

CIITA B
- O
induced O
occupation O
of O
MHC B
class I
II I
promoters I
is O
independent O
of O
the O
cooperative O
stabilization O
of O
the O
promoter B
- I
bound I
multi I
- I
protein I
complexes I
. O

In O
this O
report O
, O
we O
have O
analyzed O
the O
response O
of O
the O
hematopoietic O
precursor O
cell O
line O
32Dcl3 O
, O
expressing O
either O
the O
normal B
protein I
MDS1 I
/ I
EVI1 I
or O
the O
fusion B
protein I
AML1 I
/ I
MDS1 I
/ I
EVI1 I
, O
to O
factors O
that O
control O
cell O
differentiation O
or O
cell O
replication O
. O

The O
B B
cell I
- I
specific I
cell I
surface I
molecule I
CD19 B
is O
expressed O
at O
all O
stages O
of O
B O
cell O
development O
, O
including O
normal O
plasma O
cells O
, O
and O
mediates O
signal O
transduction O
via O
interaction O
with O
cytoplasmic B
effector I
proteins I
. O

The O
functional O
contribution O
of O
the O
kappaB B
- I
Sp1 I
composite I
site I
in O
P B
/ I
I I
- I
inducible I
fas I
promoter I
activation O
was O
verified O
by O
using O
kappaB O
- O
Sp1 B
concatamers O
( O
- B
295 I
to I
- I
286 I
) O
in O
a O
thymidine B
kinase I
promoter I
- I
driven I
reporter I
construct I
and O
native B
promoter I
constructs I
in O
Jurkat O
cells O
overexpressing O
IkappaB B
- I
alpha I
. O

The O
functional O
contribution O
of O
the O
kappaB B
- I
Sp1 I
composite I
site I
in O
P B
/ I
I I
- I
inducible I
fas I
promoter I
activation O
was O
verified O
by O
using O
kappaB O
- O
Sp1 B
concatamers O
( O
- B
295 I
to I
- I
286 I
) O
in O
a O
thymidine B
kinase I
promoter I
- I
driven I
reporter I
construct I
and O
native B
promoter I
constructs I
in O
Jurkat O
cells O
overexpressing O
IkappaB B
- I
alpha I
. O

The O
3 B
' I
- I
CAGGTG I
E I
- I
box I
could O
bind O
USF B
proteins I
, O
the O
ubiquitous B
repressor I
ZEB B
, O
or O
the O
basic B
helix I
- I
loop I
- I
helix I
proteins I
E2A B
and O
HEB B
, O
and O
we O
showed O
that O
a O
competition O
between O
ZEB B
and O
E2A B
/ I
HEB I
proteins I
is O
involved O
in O
the O
silencer O
activity O
. O

The O
3 B
' I
- I
CAGGTG I
E I
- I
box I
could O
bind O
USF B
proteins I
, O
the O
ubiquitous B
repressor I
ZEB B
, O
or O
the O
basic B
helix I
- I
loop I
- I
helix I
proteins I
E2A B
and O
HEB B
, O
and O
we O
showed O
that O
a O
competition O
between O
ZEB B
and O
E2A B
/ I
HEB I
proteins I
is O
involved O
in O
the O
silencer O
activity O
. O

In O
agar O
cultures O
, O
47 O
. O
10 O
cells O
form O
7 O
- O
and O
14 O
- O
day O
colonies O
in O
response O
to O
a O
cocktail O
of O
granulocyte B
/ I
macrophage I
colony I
- I
stimulating I
factor I
( O
2 O
. O
5 O
ng O
/ O
mL O
) O
, O
interleukin B
- I
3 I
( O
1 O
ng O
/ O
mL O
) O
, O
and O
mouse O
CSF B
- I
1 I
( O
10 O
ng O
/ O
mL O
) O
. O

In O
this O
report O
, O
we O
show O
that O
Mycoplasma B
fermentans I
lipid I
- I
associated I
membrane I
proteins I
( O
LAMPf B
) O
induce O
the O
production O
of O
high O
levels O
of O
IL B
- I
8 I
by O
THP O
- O
1 O
( O
human O
monocyte O
) O
cells O
and O
PMN O
at O
the O
same O
extent O
as O
LPS O
. O

RESULTS O
: O
We O
identified O
peptides O
derived O
from O
EWS B
/ I
FLI I
- I
1 I
fusion I
protein I
and O
from O
mutated B
K I
- I
RAS I
protein I
( O
encompassing O
respectively O
the O
fusion B
point I
and O
the O
mutation O
at O
position B
12 I
) O
that O
showed O
binding B
motif I
for O
HLA B
- I
Cw I
* I
0702 I
and O
HLA B
- I
A3 I
respectively O
. O

We O
suspect O
that O
the O
C B
/ I
EBP I
epsilon I
promoter I
/ I
enhancer I
contains O
a O
retinoic B
acid I
- I
response I
element I
that O
is O
directly O
stimulated O
by O
retinoids O
. O

Transfection O
of O
EL O
- O
4 O
cells O
with O
the O
IL B
- I
4 I
promoter I
- I
reporter I
constructs I
carrying O
mutated B
P I
- I
like I
elements I
showed O
that O
four O
P B
- I
like I
elements I
, O
CLE0 B
, O
P B
, O
P2 B
and O
P4 B
, O
but O
not O
P3 B
, O
were O
required O
for O
optimal O
activation O
of O
the O
IL B
- I
4 I
promoter I
. O

From O
these O
observations O
we O
conclude O
that O
free O
thiols O
in O
the O
IL B
- I
1RI I
complex I
are O
essential O
for O
the O
activation O
of O
the O
IL B
- I
1RI I
- I
associated I
protein I
kinase I
and O
that O
this O
process O
is O
mandatory O
for O
IL B
- I
1 I
signaling O
leading O
to O
NF B
- I
kappa I
B I
activation O
. O

These O
bHLH B
antagonists I
are O
induced O
during O
a O
mitogenic O
signalling O
response O
, O
and O
they O
function O
by O
sequestering O
their O
bHLH B
targets I
in O
inactive B
heterodimers I
that O
are O
unable O
to O
bind O
to O
specific O
gene B
regulatory I
( I
E I
box I
) I
sequences I
. O

Here O
we O
describe O
cloning O
and O
characterization O
of O
full O
- O
length O
cDNA B
encoding I
murine I
( I
m I
) I
NFATc I
which O
predicts O
that O
the O
protein O
has O
all O
the O
conserved B
structural I
motifs I
of O
NFAT B
family I
members I
, O
including O
the O
rel O
homology O
domain O
, O
the O
NFAT B
homology I
domain I
and O
the O
nuclear O
translocation O
signals O
. O

Mutation O
of O
the O
CBF1 B
/ I
RBP I
- I
Jkappa I
binding I
site I
in O
EBNA3C B
abrogated O
repression O
, O
strongly O
suggesting O
that O
CBF1 B
/ I
RBP I
- I
Jkappa I
is O
necessary O
for O
targeting O
the O
viral O
protein O
to O
Cp B
. O

The O
composite B
PU I
. I
1 I
and I
Pip I
site I
likely O
accounts O
for O
both O
lineage O
and O
stage O
- O
specific O
expression O
of O
CD20 B
whereas O
the O
CD20 B
E I
box I
binding I
proteins I
enhance O
overall O
promoter O
activity O
and O
may O
link O
the O
promoter O
to O
a O
distant B
enhancer I
. O

To O
define O
the O
CD40 B
signaling O
components O
upstream O
of O
NF B
- I
kappa I
B I
activation O
and O
the O
functional O
consequences O
downstream O
of O
NF B
- I
kappa I
B I
activation O
, O
we O
examined O
mouse O
B O
cell O
transfectants O
expressing O
wild B
- I
type I
or I
mutant I
human I
CD40 I
. O

Induction O
of O
endothelial B
cell I
surface I
adhesion I
molecules I
by O
tumor B
necrosis I
factor I
is O
blocked O
by O
protein O
tyrosine O
phosphatase O
inhibitors O
: O
role O
of O
the O
nuclear B
transcription I
factor I
NF I
- I
kappa I
B I
. O

Spi B
- I
1 I
/ I
PU I
. I
1 I
is O
a O
myeloid B
- I
and I
B I
- I
cell I
specific I
transcription I
factor I
which O
is O
also O
involved O
in O
Friend O
virus O
- O
induced O
murine O
erythroleukemia O
. O

They O
also O
suggest O
that O
the O
function O
of O
Spi B
- I
1 I
/ I
PU I
. I
1 I
in O
the O
late O
phase O
of O
Friend O
leukemia O
requires O
specific O
signaling O
from O
the O
gp55 B
- I
modified I
EpoR I
generated O
during O
the O
early O
phase O
of O
the O
disease O
. O

The O
tax B
protein I
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
mediates O
the O
transactivation O
of O
the O
c B
- I
sis I
/ I
platelet I
- I
derived I
growth I
factor I
- I
B I
promoter I
through O
interactions O
with O
the O
zinc B
finger I
transcription I
factors I
Sp1 B
and O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
. O

Interestingly O
, O
co O
- O
immunoprecipitation O
analysis O
also O
revealed O
that O
Tax B
mutant O
IEXC29S B
is O
unable O
to O
interact O
with O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
, O
whereas O
Tax B
mutant O
IEXL320G B
is O
able O
to O
interact O
with O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
. O

Interestingly O
, O
co O
- O
immunoprecipitation O
analysis O
also O
revealed O
that O
Tax B
mutant O
IEXC29S B
is O
unable O
to O
interact O
with O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
, O
whereas O
Tax B
mutant O
IEXL320G B
is O
able O
to O
interact O
with O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
. O

BACKGROUND O
: O
Recent O
studies O
have O
raised O
the O
hypothesis O
that O
glucocorticoids O
could O
diminish O
the O
ability O
of O
endothelial O
cells O
to O
direct O
leukocyte O
traffic O
into O
inflamed O
tissues O
by O
inhibiting O
expression O
of O
the O
adhesion B
molecules I
endothelial B
- I
leukocyte I
adhesion I
molecule I
- I
1 I
and O
intercellular B
adhesion I
molecule I
- I
1 I
. O

Like O
the O
class B
II I
genes I
, O
the O
HLA B
- I
DM I
genes I
contain O
upstream O
regulatory O
sequences O
similar O
to O
the O
S B
- I
X I
- I
Y I
regulatory I
region I
as O
well O
as O
additional O
putative O
regulatory O
sites O
. O

Critical O
cytoplasmic B
domains I
of O
human B
interleukin I
- I
9 I
receptor I
alpha I
chain I
in O
interleukin B
- O
9 O
- O
mediated O
cell O
proliferation O
and O
signal O
transduction O
. O

We O
report O
the O
identification O
and O
characterization O
of O
simple B
tandem I
repeat I
DNA I
polymorphisms I
in O
the O
genes O
encoding O
HNF B
- I
3alpha I
, O
- B
3beta I
, O
- B
3gamma I
, O
- B
4gamma I
, O
and O
- B
6 I
and O
the O
mapping O
of O
HNF B
- I
6 I
to O
chromosome B
bands I
15q21 B
. I
1 I
- I
21 I
. I
2 I
by O
fluorescence O
in O
situ O
hybridization O
. O

Ligand O
binding O
and O
activation O
of O
the O
IL B
- I
10 I
receptor I
expressed O
on O
B O
- O
CLL O
cells O
results O
in O
the O
phosphorylation O
of O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( O
STAT1 B
) O
and O
STAT3 B
proteins O
. O

In O
this O
report O
we O
present O
the O
characterisation O
of O
NF B
- I
kappaB I
subunits I
engaged O
in O
complexes O
binding O
to O
the O
HIV B
- I
1 I
NF I
- I
kappaB I
site I
in O
human O
8e51 O
T O
- O
cells O
, O
that O
harbour O
a O
defective O
HIV O
- O
1 O
. O

Triggering O
of O
the O
T B
- I
cell I
receptor I
- I
CD3 I
complex I
activates O
two O
major O
signal O
cascades O
in O
T O
lymphocytes O
, O
( O
i O
) O
Ca2 O
+ O
- O
dependent O
signal O
cascades O
and O
( O
ii O
) O
protein B
kinase I
cascades O
. O

Functional O
analysis O
of O
monocytic O
THP O
- O
1 O
cells O
transfected O
with O
plasmids B
containing O
various O
lengths O
of O
TNF B
- I
alpha I
promoter I
localized O
enhancer B
elements I
in O
a O
region O
( O
- B
182 I
to I
- I
37 I
base I
pairs I
( O
bp O
) O
) O
that O
were O
required O
for O
optimal O
transcription O
of O
the O
TNF B
- I
alpha I
gene I
in O
response O
to O
LPS O
. O

However O
, O
these O
plasmids B
produced O
transcriptional O
activity O
in O
HeLa O
cells O
only O
in O
conjunction O
with O
interferon B
gamma I
stimulation O
, O
a O
condition O
in O
which O
expression O
of O
both O
CIITA B
and O
class B
II I
major I
histocompatibility I
complex I
surface I
proteins I
are O
induced O
. O

These O
are O
known O
to O
bind O
to O
seven B
- I
transmembrane I
- I
domain I
containing I
receptors I
. O

Upon O
activation O
of O
Jurkat O
T O
cells O
and O
primary O
murine O
thymocytes O
with O
phorbol O
esters O
and O
ionomycin O
, O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
expression O
and O
transactivation O
function O
were O
induced O
. O

In O
contrast O
, O
somatic O
cell O
fusion O
between O
clone O
13 O
and O
RJ2 O
. O
2 O
. O
5 O
restored O
expression O
of O
the O
HLA B
- I
DQ I
haplotype O
encoded O
by O
the O
RJ2 B
. I
2 I
. I
5 I
DQB I
gene I
. O

Treatment O
of O
cells O
expressing O
the O
chimeric B
receptor I
kit B
/ I
IL I
- I
4R I
alpha I
with O
SCF B
induces O
activation O
of O
the O
IL B
- I
4R I
alpha I
- I
associated I
kinase I
JAK B
- I
1 I
and O
the O
transcription B
factor I
STAT6 B
. O

Transcriptional O
induction O
of O
collagenase B
- I
1 I
in O
differentiated O
monocyte O
- O
like O
( O
U937 O
) O
cells O
is O
regulated O
by O
AP B
- I
1 I
and O
an O
upstream B
C I
/ I
EBP I
- I
beta I
site I
. O

Using O
a O
mitogenically B
incompetent I
human I
G I
- I
CSFR I
mutant I
in O
which O
Pro639 O
and O
Pro641 O
were O
substituted O
by O
alanine O
, O
the O
box B
1 I
PDP I
motif I
was O
found O
to O
be O
required O
for O
activation O
of O
Jak B
kinases I
, O
tyrosine O
phosphorylation O
of O
the O
G B
- I
CSFR I
, O
and O
recruitment O
of O
Stat B
proteins I
. O

Activation O
of O
the O
Jak B
- B
Stat I
pathway O
correlates O
with O
proliferative O
signaling O
by O
the O
G B
- I
CSFR I
and O
requires O
the O
membrane B
- I
proximal I
box I
1 I
PXP I
motif I
, O
which O
is O
conserved O
in O
members O
of O
the O
cytokine B
receptor I
superfamily I
. O

Moreover O
, O
EGF O
treatment O
induced O
Stat3 B
phosphorylation O
in O
cells O
transfected O
with O
the O
intact O
chimeric B
EGF I
- I
gp130 I
receptor I
along O
with O
induction O
of O
DNA O
- O
mobility O
shift O
of O
a O
classical B
interferon I
- I
gamma I
- I
activated I
site I
. O

Stimulation O
with O
either O
PAF B
or O
FMLP B
resulted O
in O
equivalent O
phosphorylation O
and O
activation O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( I
MAPk I
) I
homologue I
38 B
- I
kD I
murine I
MAP I
kinase I
homologous O
to O
HOG B
- I
1 I
( I
p38 I
) I
MAPk I
. O

Co O
- O
ligation O
of O
the O
A6H B
antigen O
and O
the O
CD3 B
complex I
induced O
expression O
of O
the O
transcription B
factor I
AP B
- I
1 I
in O
CD4 O
+ O
T O
cells O
, O
whereas O
no O
increase O
in O
NF B
- I
kappa I
B I
and O
octamer B
- I
binding I
( I
Oct I
) I
proteins I
was O
seen O
compared O
to O
T O
cells O
stimulated O
with O
anti B
- I
CD3 I
alone O
. O

Elf B
- I
2 I
, O
a O
rhombotin B
- I
2 I
binding I
ets I
transcription I
factor I
: O
discovery O
and O
potential O
role O
in O
T O
cell O
leukemia O
. O

3BP2 B
was O
selectively O
expressed O
in O
hematopoietic O
/ O
lymphoid O
tissues O
and O
bound O
via O
its O
SH2 B
domain I
activated I
Syk I
- I
family I
kinases I
in O
mammalian O
cells O
, O
including O
in O
antigen O
receptor O
- O
stimulated O
T O
cells O
. O

The O
role O
of O
Aiolos B
, O
a O
lymphoid B
- I
restricted I
and I
structurally I
related I
gene I
, O
in O
lymphoid O
differentiation O
is O
discussed O
. O

STAT1 B
pathway O
is O
involved O
in O
activation O
of O
caprine O
arthritis B
- I
encephalitis I
virus I
long I
terminal I
repeat I
in O
monocytes O
. O

1 B
, I
25 I
- I
Dihydroxyvitamin I
D3 I
receptors I
in O
peripheral O
blood O
mononuclear O
cells O
from O
patients O
with O
renal O
insufficiency O
. O

A O
novel O
transcription B
factor I
regulates O
expression O
of O
the O
vacuolar B
H I
+ I
- I
ATPase I
B2 I
subunit I
through O
AP B
- I
2 I
sites I
during O
monocytic O
differentiation O
. O

These O
findings O
suggest O
that O
a O
novel O
AP B
- I
2 I
- I
like I
transcription I
factor I
is O
responsible O
for O
V B
- I
ATPase I
B I
subunit I
amplification O
during O
monocyte O
differentiation O
. O

Both O
BZLF1 B
and I
BRLF1 I
immediate I
- I
early I
transcripts I
, O
but O
not O
BMLF1 B
transcript I
, O
could O
be O
detected O
in O
individual O
CD4 O
+ O
and O
CD8 O
+ O
T O
cells O
infected O
with O
EBV O
. O

The O
first O
step O
in O
the O
nuclear O
import O
process O
is O
recognition O
of O
a O
nuclear B
localization I
sequence I
( O
NLS B
) O
within O
the O
karyophilic B
protein I
by O
a O
cytoplasmic B
receptor I
such O
as O
the O
importin B
( I
karyopherin I
) I
- I
alpha I
subunit I
. O

These O
studies O
revealed O
that O
the O
major B
protein I
in O
extracts O
of O
PMN O
activated O
by O
G B
- I
CSF I
to O
bind O
the O
high B
- I
affinity I
serum I
- I
inducible I
element I
( O
hSIE B
) O
is O
a O
72 B
- I
kDa I
protein I
that O
cross O
- O
reacts O
with O
Stat3 B
monoclonal I
antibody I
, O
which O
we O
have O
designated O
Stat3gamma B
. O

The O
action O
of O
adenoviral B
E1A I
oncoprotein I
on O
host B
immune I
- I
response I
genes I
has O
been O
attributed O
to O
interaction O
with O
p300 B
/ I
CBP I
- I
type I
transcriptional I
coactivators I
in O
competition O
with O
endogenous B
transcription I
factors I
such O
as O
signal B
transducer I
and I
activator I
of I
transcription I
( I
STAT I
) I
proteins I
. O

An O
81 O
% O
increment O
in O
promoter O
activity O
was O
obtained O
when O
a O
mutation O
was O
introduced O
in O
the O
GATA B
- I
3 I
binding I
site I
of O
the O
bp B
- I
267 I
to I
+ I
12 I
construct I
, O
which O
is O
comparable O
to O
that O
of O
the O
bp B
- I
245 I
to I
+ I
12 I
construct I
. O

An O
81 O
% O
increment O
in O
promoter O
activity O
was O
obtained O
when O
a O
mutation O
was O
introduced O
in O
the O
GATA B
- I
3 I
binding I
site I
of O
the O
bp B
- I
267 I
to I
+ I
12 I
construct I
, O
which O
is O
comparable O
to O
that O
of O
the O
bp B
- I
245 I
to I
+ I
12 I
construct I
. O

Both O
Tax B
- O
mediated O
apoptosis O
and O
oxidative O
stress O
can O
be O
potently O
suppressed O
by O
antioxidants O
, O
as O
is O
seen O
with O
the O
administration O
of O
recombinant B
thioredoxin I
( O
adult B
T I
cell I
leukemia I
- I
derived I
factor I
) O
or O
pyrrolidine O
dithiocarbamate O
. O

Signal B
transducer I
and I
activator I
of I
transcription I
3 I
( O
Stat3 B
) O
has O
recently O
been O
shown O
to O
exist O
in O
two O
alternatively O
spliced O
isoforms O
, O
a O
short O
form O
, O
Stat3beta B
, O
and O
a O
longer O
form O
, O
Stat3alpha B
, O
displaying O
differences O
in O
transcriptional O
activity O
. O

The O
cytokine B
- O
dependent O
upregulation O
of O
the O
murine B
macrophage I
12 I
- I
lipoxygenase I
and O
its O
induction O
during O
experimental O
anemia O
suggests O
its O
close O
relatedness O
with O
the O
human B
reticulocyte I
- I
type I
15 I
- I
lipoxygenase I
despite O
their O
differences O
in O
the O
positional O
specificity O
of O
arachidonic O
acid O
oxygenation O
. O

Interferon B
- I
gamma I
- I
induced I
factor I
binding O
to O
the O
interleukin B
- I
4 I
- I
responsive I
element I
of O
CD23b B
promoter I
in O
human O
tonsillar O
mononuclear O
cells O
: O
role O
in O
transient O
up O
- O
regulation O
of O
the O
interleukin B
- I
4 I
- I
induced I
CD23b I
mRNA I
. O

The O
functions O
of O
NFAT B
proteins I
are O
directly O
controlled O
by O
the O
calcium B
- I
and I
calmodulin I
- I
dependent I
phosphatase I
calcineurin B
. O

Thus O
, O
compared O
with O
findings O
in O
control O
cells O
, O
class B
II I
molecules I
in O
infected O
cells O
colocalized O
to O
a O
minimal O
extent O
with O
a O
lysosomal B
- I
associated I
membrane I
protein I
- I
1 I
+ O
endosomal O
compartment O
. O

Analyzed O
DNA B
sequences I
included O
delta B
and I
beta I
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
500 I
to I
+ I
50bp I
( O
promoter B
regions I
) O
, O
truncated O
delta O
and O
beta B
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
250 I
to I
+ I
50 I
bp I
, O
and O
chimeric B
promoter I
constructions I
, O
which O
consisted O
of O
a O
distal O
delta B
or I
beta I
fragment I
fused O
to O
a O
proximal B
beta I
or I
delta I
sequence I
. O

To O
evaluate O
a O
potential O
mechanism O
for O
these O
differences O
in O
function O
, O
we O
evaluated O
expression O
of O
protein B
kinase I
C I
( I
PKC I
) I
isoforms I
. O

Dominant O
negative O
forms O
of O
Stat1alpha B
or O
Stat3 B
promoted O
the O
EPO B
- O
induced O
erythroid O
differentiation O
of O
UT O
- O
7 O
/ O
GM O
cells O
, O
even O
in O
the O
presence O
of O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
, O
although O
this O
cytokine O
never O
induced O
erythroid O
differentiation O
of O
the O
parent O
UT O
- O
7 O
/ O
GM O
cells O
with O
or O
without O
EPO B
. O

MyD88 B
, O
originally O
isolated O
as O
a O
myeloid O
differentiation O
primary B
response I
gene I
, O
is O
shown O
to O
act O
as O
an O
adaptor O
in O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
signaling O
by O
interacting O
with O
both O
the O
IL B
- I
1 I
receptor I
complex I
and O
IL B
- I
1 I
receptor I
- I
associated I
kinase I
( O
IRAK B
) O
. O

Furthermore O
, O
IL B
- I
18 I
- O
induced O
activation O
of O
NF B
- I
kappaB I
and O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( O
JNK B
) O
is O
blocked O
in O
MyD88 O
- O
/ O
- O
Th1 O
- O
developing O
cells O
. O

The O
implication O
of O
protein B
tyrosine I
kinase I
( I
s I
) I
, O
protein B
kinase I
A I
and O
/ O
or O
protein B
kinase I
C I
was O
highlighted O
by O
the O
abrogation O
of O
the O
ManLAM O
- O
mediated O
activation O
of O
HIV B
- I
1 I
LTR I
- I
driven I
gene I
expression O
using O
herbimycin O
A O
and O
H7 O
. O

In O
this O
study O
we O
analyzed O
the O
T B
cell I
receptor I
( I
TcR I
) I
delta I
transcripts I
expressed O
by O
CD3 O
- O
CD16 O
+ O
cells O
and O
we O
investigated O
whether O
these O
cells O
expressed O
the O
hGATA B
- I
3 I
T I
cell I
transcription I
factor I
and O
the O
recombination B
- I
activating I
gene I
( I
RAG I
) I
- I
1 I
. O

Activation O
of O
the O
HIV O
- O
1 O
provirus O
correlated O
with O
the O
activation O
of O
binding O
of O
55 B
- I
and I
85 I
- I
kDa I
proteins I
to O
the O
kappa B
B I
enhancer I
and O
binding O
of O
the O
50 B
- I
kDa I
HLP I
- I
1 I
protein I
to O
the O
LBP B
- I
1 I
sequences I
of O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
. O

Activation O
of O
the O
HIV O
- O
1 O
provirus O
correlated O
with O
the O
activation O
of O
binding O
of O
55 B
- I
and I
85 I
- I
kDa I
proteins I
to O
the O
kappa B
B I
enhancer I
and O
binding O
of O
the O
50 B
- I
kDa I
HLP I
- I
1 I
protein I
to O
the O
LBP B
- I
1 I
sequences I
of O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
. O

Cell O
- O
type O
- O
specific O
transactivation O
of O
the O
parathyroid B
hormone I
- I
related I
protein I
gene I
promoter I
by O
the O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
tax I
and O
HTLV B
- I
II I
tax I
proteins I
. O

In O
contrast O
, O
the O
binding O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
to O
its O
response O
element O
in O
the O
IL2 B
enhancer I
and O
to O
an O
NF B
- I
AT I
- I
like I
response I
element I
present O
in O
the O
IL4 B
enhancer I
was O
abnormal O
. O

A O
cell B
- I
type I
- I
independent I
lipopolysaccharide I
( I
LPS I
) I
- I
responsive I
enhancer I
element I
located O
between O
- B
3757 I
and I
- I
2729 I
bp I
upstream I
from O
the O
transcription B
start I
site I
( O
cap B
site I
) O
consisted O
of O
at O
least O
six O
discrete O
subregions O
which O
were O
essential O
to O
the O
maximal O
induction O
by O
LPS O
in O
transfected O
monocytes O
. O

Competition O
with O
an O
AP B
- I
1 I
motif I
or O
with O
anti B
- I
Jun I
and O
anti B
- I
Fos I
antibodies I
abolished O
binding O
to O
the O
NFAT B
motif I
in O
both O
T O
and O
B O
cells O
, O
indicating O
that O
Jun O
and O
Fos O
are O
critical O
for O
NFAT B
complex I
formation O
in O
both O
cell O
types O
. O

G0S24 B
is O
a O
member O
of O
a O
set O
of O
genes O
( O
putative B
G0 I
/ I
G1 I
switch I
regulatory I
genes I
) O
that O
are O
expressed O
transiently O
within O
1 O
- O
2 O
hr O
of O
the O
addition O
of O
lectin B
or O
cycloheximide O
to O
human O
blood O
mononuclear O
cells O
. O

We O
report O
the O
characterization O
of O
the O
cis B
- I
and I
trans I
- I
acting I
elements I
involved O
in O
the O
tissue O
- O
specific O
activity O
of O
the O
L B
gene I
erythroid I
promoter I
. O

Increased O
c B
- I
jun I
, O
jun B
- I
B I
, O
and O
jun B
- I
D I
expression O
above O
basal O
levels O
and O
increased O
transcriptional O
activity O
of O
AP B
- I
1 I
/ I
TPA I
responsive I
elements I
fused O
to O
chloramphenicol B
acetyl I
- I
transferase I
vectors I
were O
observed O
in O
T O
cells O
treated O
with O
TPA O
alone O
or O
in O
combination O
with O
dexamethasone O
. O

Human B
immunodeficiency I
virus I
type I
1 I
Nef I
protein I
inhibits O
NF B
- I
kappa I
B I
induction O
in O
human O
T O
cells O
. O

These O
results O
indicate O
that O
defective O
recruitment O
of O
NF B
- I
kappa I
B I
may O
underlie O
Nef B
' O
s O
negative O
transcriptional O
effects O
on O
the O
HIV B
- I
1 I
and I
interleukin I
2 I
promoters I
. O

The O
long B
terminal I
repeat I
( I
LTR I
) I
region I
of O
HIV B
proviral I
DNA I
contains O
binding O
sites O
for O
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
and O
this O
transcriptional B
activator I
appears O
to O
regulate O
HIV O
activation O
. O

In O
this O
article O
, O
transcriptional O
regulation O
of O
the O
archetypal B
T I
- I
cell I
- I
specific I
gene I
, O
alpha B
TCR I
, O
is O
discussed O
. O

Analysis O
of O
the O
p50 B
and O
p65 B
subunits I
of O
the O
NF B
- I
kappa I
B I
transcription I
factor I
complex I
has O
revealed O
that O
both O
proteins O
can O
interact O
with O
related O
DNA O
sequences O
through O
either O
homo O
- O
or O
heterodimer O
formation O
. O

Mutations O
affecting O
the O
5 B
' I
guanine I
residues I
of O
the O
kappa B
B I
site I
were O
unable O
to O
compete O
for O
these O
NF B
- I
kappa I
B I
- I
related I
proteins I
. O

Together O
, O
these O
findings O
suggest O
that O
the O
nuclear O
localization O
signal O
and O
transactivation B
domain I
of O
NF B
- I
kappa I
B I
p65 I
constitute O
a O
bipartite O
system O
that O
is O
critically O
involved O
in O
the O
inhibitory O
function O
of O
I B
kappa I
B I
/ I
MAD I
- I
3 I
. O

In O
THP O
- O
1 O
cells O
, O
TPA O
also O
induced O
a O
new O
, O
faster B
- I
migrating I
NF I
kappa I
B I
species I
not O
induced O
in O
monocytes O
. O

We O
have O
found O
that O
the O
p49 B
( I
100 I
) I
DNA I
binding I
subunit I
, O
together O
with O
p65 B
, O
can O
act O
in O
concert O
with O
Tat B
- I
I I
to O
stimulate O
the O
expression O
of O
HIV B
- I
CAT I
plasmid I
. O

In O
the O
studies O
described O
in O
this O
report O
, O
we O
have O
identified O
two O
potential O
Ets B
binding I
sites I
, O
EBS1 O
and O
EBS2 B
, O
which O
are O
conserved O
in O
both O
the O
human B
and I
murine I
interleukin I
- I
2 I
enhancers I
. O

Furthermore O
, O
an O
antiserum O
against O
KBF1 B
( O
identical O
to O
50 B
kDa I
NF I
- I
kappa I
B I
protein I
) O
reacted O
with O
the O
p50 B
of O
NF B
- I
GM2 I
, O
indicating O
that O
the O
NF B
- I
GM2 I
polypeptide I
can O
not O
be O
immunologically O
differentiated O
from O
the O
50 B
kDa I
subunit I
of O
NF B
- I
kappa I
B I
. O

This O
probe O
was O
used O
to O
identify O
a O
rel B
- I
related I
complementary I
DNA I
that O
hybridized O
to O
a O
2 B
. I
6 I
- I
kilobase I
messenger I
RNA I
present O
in O
human O
T O
and O
B O
lymphocytes O
. O

The O
v B
- I
erbA I
oncoprotein I
represents O
a O
retrovirus O
- O
transduced O
oncogenic O
version O
of O
the O
thyroid B
hormone I
( I
T3 I
/ I
T4 I
) I
receptor I
c B
- I
erbA I
( I
type I
alpha I
) I
. O

Inhibition O
of O
transcription B
factors I
belonging O
to O
the O
rel B
/ I
NF I
- I
kappa I
B I
family I
by O
a O
transdominant B
negative I
mutant I
. O

The O
murine B
and I
human I
factors I
are O
abundantly O
expressed O
in O
a O
variety O
of O
human O
and O
murine O
T O
- O
cell O
lines O
and O
can O
activate O
transcription O
through O
a O
tissue B
- I
specific I
GATA I
- I
binding I
site I
identified O
within O
the O
human B
T I
- I
cell I
receptor I
delta I
gene I
enhancer I
. O

A O
thymus B
- I
specific I
member I
of O
the O
HMG B
protein I
family I
regulates O
the O
human B
T I
cell I
receptor I
C I
alpha I
enhancer I
. O

The O
human B
T I
cell I
- I
specific I
transcription I
factor I
TCF B
- I
1 I
alpha I
plays O
a O
key O
role O
in O
the O
tissue O
- O
specific O
activation O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
C O
alpha O
enhancer O
and O
binds O
to O
pyrimidine B
- I
rich I
elements I
( O
5 O
' O
- O
PyCTTTG O
- O
3 O
' O
) O
present O
in O
a O
variety O
of O
other O
T B
cell I
- I
specific I
control I
regions I
. O

TCF B
- I
1 I
alpha I
is O
currently O
unique O
among O
the O
newly O
emerging O
family O
of O
DNA B
- I
binding I
regulatory I
proteins I
that O
share O
the O
HMG B
motif I
in O
that O
it O
is O
a O
highly B
tissue I
- I
specific I
RNA I
polymerase I
II I
transcription B
factor I
. O

Thus O
, O
both O
NF B
- I
kappa I
B I
- I
binding I
complexes I
are O
needed O
for O
optimal O
viral O
transcription O
. O

Role O
for O
the O
Epstein B
- I
Barr I
virus I
nuclear I
antigen I
2 I
in O
viral B
promoter I
switching O
during O
initial O
stages O
of O
infection O
. O

These O
studies O
have O
been O
extended O
to O
show O
that O
( O
i O
) O
a O
mutant O
EBV O
strain O
lacking O
the O
gene O
encoding O
EBNA B
2 I
fails O
to O
switch O
from O
Wp O
to O
Cp B
usage O
in O
primary O
B O
lymphocytes O
, O
although O
the O
virus O
contains O
a O
functional O
Cp B
; O
( O
ii O
) O
a O
region O
from O
- B
429 I
to I
- I
245 I
base I
pairs I
upstream O
of O
Cp B
is O
essential O
for O
Cp B
activity O
in O
B O
lymphocytes O
, O
but O
only O
in O
the O
context O
of O
upstream B
and I
downstream I
sequences I
; O
( O
iii O
) O
this O
region O
contains O
an O
EBNA B
2 I
- I
dependent I
enhancer I
; O
and O
( O
iv O
) O
DNase B
I I
protection O
employing O
nuclear O
extracts O
from O
B O
and O

TCF B
- I
1 I
belonged O
to O
a O
novel O
family O
of O
genes O
that O
contain O
the O
so O
- O
called O
high O
mobility B
group I
1 I
( I
HMG I
) I
box I
. O

There O
is O
a O
single O
methionine B
codon I
- I
initiated I
open I
reading I
frame I
of O
1 O
, O
458 O
nt O
in O
frame O
with O
a O
homeobox B
and O
a O
CAX B
repeat I
, O
and O
the O
open B
reading I
frame I
is O
predicted O
to O
encode O
a O
protein O
of O
51 O
, O
659 O
daltons O
. O

Tandem O
copies O
of O
this O
67 B
- I
bp I
MnlI I
- I
AluI I
fragment I
, O
when O
fused O
to O
the O
chloramphenicol B
acetyltransferase I
gene I
driven O
by O
the O
conalbumin B
promoter I
, O
stimulated O
transcription O
in O
B O
cells O
but O
not O
in O
Jurkat O
T O
cells O
or O
HeLa O
cells O
. O

Starting O
with O
a O
replication O
- O
incompetent O
molecular O
clone O
of O
human O
immunodeficiency O
virus O
type O
1 O
, O
lacking O
all O
the O
NF B
- I
kappa I
B I
and I
Sp1 I
binding I
sites I
present O
in O
the O
native B
long I
terminal I
repeat I
( O
LTR B
) O
, O
proviruses O
containing O
reconstructed B
LTRs I
with O
individual O
or O
combinations O
of O
NF B
- I
kappa I
B I
and I
Sp1 I
elements I
were O
generated O
and O
evaluated O
for O
their O
capacity O
to O
produce O
virus O
progeny O
following O
transfection O
- O
cocultivation O
. O

Cell O
- O
specific O
differences O
in O
activation O
of O
NF B
- I
kappa I
B I
regulatory I
elements I
of O
human B
immunodeficiency I
virus I
and I
beta I
interferon I
promoters I
by O
tumor B
necrosis I
factor I
. O

Type B
- I
II I
estrogen I
- I
binding I
sites I
( O
type B
- I
II I
EBS I
) O
have O
been O
demonstrated O
in O
the O
human O
lymphoblastoid O
cell O
line O
IM O
- O
9 O
using O
a O
whole O
- O
cell O
assay O
with O
( O
6 O
, O
7 O
- O
3H O
) O
estradiol O
( O
3H O
- O
E2 O
) O
as O
tracer O
. O

The O
tissue O
- O
specific O
expression O
of O
the O
MOPC B
141 I
immunoglobulin I
heavy I
- I
chain I
gene I
was O
studied O
by O
using O
in O
vitro O
transcription O
. O

The O
same O
agents O
induce O
transcription O
from O
the O
interleukin B
- I
2 I
receptor I
alpha I
- I
chain I
and I
interleukin I
- I
2 I
genes I
, O
depending O
on O
promoter B
elements I
that O
bind O
the O
inducible B
transcription I
factor I
NF B
- I
kappa I
B I
( O
or O
an O
NF B
- I
kappa I
B I
- I
like I
factor I
) O
. O

Over O
a O
72 O
- O
hr O
period O
of O
activation O
, O
the O
expression O
of O
the O
50 B
- I
kDa I
NF I
- I
kappa I
B I
, O
p50 B
, O
and O
its O
precursor O
, O
p105 B
, O
was O
increased O
progressively O
. O

The O
results O
of O
supershift O
assays O
using O
NFATp B
- I
and I
NFATc I
- I
specific I
antibodies I
indicate O
that O
NK O
cell O
activation O
early O
after O
CD16 B
ligand O
binding O
involves O
primarily O
, O
if O
not O
exclusively O
, O
NFATp B
, O
and O
Western O
blot O
analysis O
shows O
that O
this O
has O
the O
same O
electrophoretic O
mobility O
( O
approximately O
120 O
kD O
) O
as O
that O
of O
T O
lymphocytes O
. O

Our O
studies O
provide O
an O
explanation O
for O
a O
previous O
observation O
that O
TCRG B
mRNA I
levels O
, O
but O
not O
mRNA O
levels O
for O
T B
cell I
receptor I
alpha I
and I
- I
beta I
, O
are O
increased O
by O
ionomycin O
treatment O
. O

To O
identify O
osteoblast B
- I
specific I
cis I
- I
acting I
elements I
and O
trans B
- I
acting I
factors I
, O
we O
initiated O
an O
analysis O
of O
the O
promoter B
of O
a O
mouse B
osteocalcin I
gene I
, O
an O
osteoblast B
- I
specific I
gene I
. O

These O
studies O
are O
the O
first O
to O
determine O
the O
structure O
and O
organization O
of O
the O
5 O
' O
end O
of O
the O
thromboxane B
receptor I
gene I
and O
demonstrate O
that O
thromboxane B
receptor I
gene I
expression O
can O
be O
regulated O
by O
activation O
of O
protein B
kinase I
C I
via O
induction O
of O
an O
AP B
- I
2 I
- I
like I
nuclear I
factor I
binding O
to O
upstream B
promoter I
elements I
. O

This O
death O
- O
promoting O
activity O
of O
Bik B
can O
be O
suppressed O
by O
coexpression O
of O
Bcl B
- I
2 I
, O
Bcl B
- I
XL I
, O
EBV B
- I
BHRF1 I
and O
E1B B
- I
19 I
kDa I
proteins O
suggesting O
that O
Bik B
may O
be O
a O
common O
target O
for O
both O
cellular B
and I
viral I
anti I
- I
apoptotic I
proteins I
. O

We O
report O
here O
that O
both O
NF B
- I
M I
- I
dependent I
promoter I
constructs I
and O
resident O
genes O
could O
be O
activated O
by O
addition O
of O
beta O
- O
estradiol O
to O
the O
NF O
- O
M O
- O
estrogen O
receptor O
expressing O
progenitors O
. O

Granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
is O
one O
such O
cytokine B
whose O
increased O
expression O
results O
partly O
from O
increases O
in O
transcription O
. O

The O
NH2 B
- I
terminal I
126 I
amino I
acids I
of O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
are O
both O
essential O
and O
sufficient O
for O
interaction O
with O
the O
POU B
domains I
of O
either O
Oct1 B
or O
Oct2 B
. O

As O
this O
phosphorylation O
was O
independent O
of O
protein B
kinase I
C I
activity O
, O
we O
tested O
whether O
a O
calcium B
/ I
calmodulin I
- I
dependent I
protein I
kinase I
( O
CaM B
kinase I
) O
might O
phosphorylate O
the O
Ets B
- I
1 I
protein I
after O
elevation O
of O
intracellular O
free O
calcium O
concentrations O
. O

Because O
HLA B
class I
II I
molecules I
present O
antigen O
to O
T B
cell I
receptors I
( O
TCRs B
) O
, O
we O
have O
searched O
for O
a O
TCR B
gene I
associated O
with O
the O
production O
of O
anti B
- I
Ro I
( I
SSA I
) I
antibodies I
. O

Human B
IL4 I
promoter I
- O
mediated O
transcription O
is O
downregulated O
in O
Jurkat O
cells O
stimulated O
with O
the O
NF B
- I
kappa I
B I
- I
activating I
cytokine I
tumor B
necrosis I
factor I
alpha I
and O
suppressed O
in O
RelA O
- O
overexpressing O
cells O
. O

Monocytic O
cell O
lines O
and O
normal O
peripheral O
blood O
monocytes O
were O
infected O
with O
HIV O
- O
1 O
in O
vitro O
and O
cultured O
in O
the O
presence O
or O
absence O
of O
F B
( I
ab I
' I
) I
2 I
fragments I
of O
monoclonal B
anti I
- I
CR1 I
or O
anti B
- I
CR3 I
Abs I
or O
with O
C3 B
fragments I
. O

We O
therefore O
examined O
vitamin O
D3 O
- O
mediated O
repression O
of O
activated O
IL B
- I
2 I
expression O
by O
cotransfecting O
Jurkat O
cells O
with O
IL B
- I
2 I
promoter I
/ I
reporter I
constructs I
and O
a O
VDR B
overexpression I
vector I
and O
by O
DNA O
binding O
. O

As O
neutralizing B
anti I
- I
IL I
- I
6 I
Abs I
effectively O
down O
- O
regulated O
the O
early O
induction O
of O
STAT B
proteins I
and O
as O
exogenously O
added O
IL B
- I
6 I
rapidly O
activated O
DNA O
binding O
similar O
to O
TCR B
- O
mediated O
bindings O
, O
it O
can O
be O
concluded O
that O
IL B
- I
6 I
is O
the O
factor O
responsible O
for O
the O
activation O
of O
STAT B
proteins I
in O
a O
primary O
T O
cell O
response O
. O

